Stay updated on Combining GEN0101 and Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Combining GEN0101 and Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Combining GEN0101 and Pembrolizumab in Melanoma Clinical Trial page
- Check6 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check21 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check43 days agoChange DetectedRevision: v3.4.2 has been added and the government funding status notice, along with the Revision: v3.4.1 label, was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check50 days agoChange DetectedA government funding/status notice was added and the page template updated to Revision: v3.4.1, replacing the previous v3.4.0.SummaryDifference0.4%

- Check57 days agoChange DetectedFooter and help-section updates were made, including glossary display and IPD-related links. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference55%

- Check93 days agoChange DetectedA new Locations section is added, listing Osaka and additional prefectures (Aichi-ken, Hokkaido, Kumamoto, Shizuoka, Tokyo) and the page revision updated to v3.3.3. The HHS Vulnerability Disclosure link and prior location entries (Aichi-ken Locations, Hokkaido Locations, Kumamoto Locations, Shizuoka Locations, Tokyo Locations) were removed.SummaryDifference0.6%

Stay in the know with updates to Combining GEN0101 and Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combining GEN0101 and Pembrolizumab in Melanoma Clinical Trial page.